The invention describes novel nitrosated and/or nitrosylated H2 receptor
antagonist compounds, and novel compositions comprising at least one H2 receptor
antagonist compound that is optionally substituted with at least one NO and/or
NO2 group, and, optionally, at least one compound that donates, transfers
or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates
endogenous levels of endothelium-derived relaxing factor or is a substrate for
nitric oxide synthase and/or at least one nonsteroidal antiinflammatory drug, antacid,
bismuth-containing reagent or anti-viral agent. The invention also describes methods
for treating and/or preventing gastrointestinal disorders; improving gastroprotective
properties of H2 receptor antagonists; decreasing the recurrence of
ulcers; facilitating ulcer healing; preventing and/or treating inflammations and
microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and
viral infections; and decreasing or reducing the gastrointestinal toxicity associated
with the use of nonsteroidal antiinflammatory compounds.
